| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-30 | Medivir (Sweden) Swedish county councils (Sweden) | Olysio® (simeprevir) | genotype 1 and hepatitis C | collaboration | Infectious diseases | Collaboration agreement |
| 2014-10-30 | Ariana Pharma (France) WIN Consortium | collaboration |
Cancer - Oncology | Collaboration agreement | ||
| 2014-10-30 | BMS (USA - NY) Lonza (Switzerland) | undisclosed biologic medicine | undisclosed | production manufacturing |
undisclosed | Production agreement |
| 2014-10-30 | Abivax (France) | nomination |
Infectious diseases - Cancer - Oncology | Nomination | ||
| 2014-10-30 | Impax (USA - CA) | R&D reorganization |
Establishment of a new subsidiary in the EU | |||
| 2014-10-30 | Chugai Pharmaceutical (Japan) Epivax (USA - RI) | Interactive Protein Screening and Reengineering Interface (ISPRI) | licensing |
Technology - Services | Licensing agreement | |
| 2014-10-30 | Vect-Horus (France) | director | nomination | Technology - Services | Nomination | |
| 2014-10-29 | Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) | portfolio of diabetes compounds including linagliptin, BI10773 and two basal insulin analogues—LY2605541 and LY2963016 | diabetes | development |
Metabolic diseases | Development agreement |
| 2014-10-29 | Alnylam Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2014-10-29 | Eurofins Genomics (Germany) Igenbio (USA - IL) | sequencing and analysis services for microbial, fungal and algal organisms | collaboration
|
Technology - Services | Collaboration agreement | |
| 2014-10-29 | NeuroSearch (Denmark) Saniona (Sweden) | NS2359 and NS2330 (tesofensine) | obesity | product acquisition |
Metabolic diseases | Product acquisition |
| 2014-10-29 | Sanofi (France) | resignation |
Resignation | |||
| 2014-10-28 | CSL Behring (Australia) Enable Injections (USA - OH) | undisclosed drug delivery system | development |
Rare diseases | Development agreement | |
| 2014-10-28 | Polyplus-transfection (France) Blue Sky BioServices (USA - MA) | PEI-based transfection technologies | R&D licensing commercialisation |
Technology - Services | Licensing agreement | |
| 2014-10-28 | Qiagen (The Netherlands) Astellas Pharma (Japan) | companion diagnostics for ASP5878, a fibroblast growth factor receptor (FGFR) inhibitor, and ASP8273, an EGFR inhibitor | development |
Cancer - Oncology | Development agreement | |
| 2014-10-28 | Sanofi (France) | resignation |
Resignation | |||
| 2014-10-28 | Catalyst Pharmaceutical Partners (USA - FL) | vice president | nomination | Rare diseases | Nomination | |
| 2014-10-28 | Juventas Therapeutics (USA - OH) | vice president | nomination | Cardiovascular diseases | Nomination | |
| 2014-10-28 | Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ) | marizomib, bevacizumab | glioblastoma | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2014-10-28 | Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ) | bispecific antibody | Establishment of a new subsidiary in the EU |
